Values First Advisors Inc. Takes $59,000 Position in Inozyme Pharma, Inc. (NASDAQ:INZY)

Values First Advisors Inc. purchased a new position in shares of Inozyme Pharma, Inc. (NASDAQ:INZY) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 13,898 shares of the company’s stock, valued at approximately $59,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Adage Capital Partners GP L.L.C. grew its holdings in Inozyme Pharma by 30.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 5,537,500 shares of the company’s stock worth $23,258,000 after purchasing an additional 1,287,500 shares during the period. Pivotal bioVenture Partners Investment Advisor LLC grew its holdings in Inozyme Pharma by 22.8% during the third quarter. Pivotal bioVenture Partners Investment Advisor LLC now owns 4,494,851 shares of the company’s stock worth $18,878,000 after purchasing an additional 833,333 shares during the period. Rock Springs Capital Management LP grew its holdings in Inozyme Pharma by 7.4% during the third quarter. Rock Springs Capital Management LP now owns 3,681,174 shares of the company’s stock worth $15,461,000 after purchasing an additional 253,090 shares during the period. Eventide Asset Management LLC acquired a new stake in Inozyme Pharma during the third quarter worth approximately $13,125,000. Finally, FMR LLC lifted its position in Inozyme Pharma by 229.2% during the third quarter. FMR LLC now owns 2,465,232 shares of the company’s stock worth $10,354,000 after acquiring an additional 1,716,398 shares during the last quarter. Institutional investors own 88.30% of the company’s stock.

Wall Street Analysts Forecast Growth

INZY has been the subject of several research reports. Wedbush restated an “outperform” rating and set a $15.00 price objective on shares of Inozyme Pharma in a research report on Tuesday, March 12th. HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of Inozyme Pharma in a research report on Wednesday, March 13th.

Inozyme Pharma Trading Up 3.7 %

INZY traded up $0.27 during trading on Thursday, reaching $7.66. 1,258,228 shares of the stock traded hands, compared to its average volume of 541,895. The company has a quick ratio of 13.36, a current ratio of 13.36 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $473.16 million, a PE ratio of -5.51 and a beta of 1.34. The stock’s 50-day moving average is $5.77 and its 200 day moving average is $4.50. Inozyme Pharma, Inc. has a 12 month low of $2.69 and a 12 month high of $7.72.

Inozyme Pharma (NASDAQ:INZY) last issued its quarterly earnings results on Tuesday, March 12th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.04). Equities analysts anticipate that Inozyme Pharma, Inc. will post -1.48 earnings per share for the current year.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.